How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years
ObjectiveWe aimed to study the epidemiology of the prodromal and mild stages of Alzheimer’s disease (AD) patients who are eligible for clinical trials with disease-modifying therapies.SettingsWe analysed two large complementary databases to study the incidence and characteristics of this population...
Main Authors: | Didier Hannequin, Florence Pasquier, Bruno Dubois, David Wallon, Julien Dumurgier, Stéphane Epelbaum, Thérèse Jonveaux, Annick Besozzi, Stéphane Pouponneau, Caroline Hommet, Laetitia Berly, Adrien Julian, Marc Paccalin, Julie Bellet, Claire Boutoleau-Bretonniere, Thiphaine Charriau, Olivier Rouaud, Olivier Madec, Aurélie Mouton, Renaud David, Samir Bekadar, Roxane Fabre, Walter Deberdt |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-06-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/9/6/e029663.full |
Similar Items
-
Comportement et dégénérescence frontotemporale : apport de la cohorte nantaise, développement de l'échelle DAPHNE et données neuropsychologiques
by: Boutoleau-Bretonnière, Claire
Published: (2015) -
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.
by: Hélène-Marie Lanoiselée, et al.
Published: (2017-03-01) -
Etude préclinique et clinique de la phase précoce de la maladie d'Alzheimer
by: Epelbaum, Stéphane
Published: (2015) -
Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ42/40 ratio
by: Hélène Pouclet‐Courtemanche, et al.
Published: (2019-12-01) -
DAPHNE: A New Tool for the Assessment of the Behavioral Variant of Frontotemporal Dementia
by: Claire Boutoleau-Bretonnière, et al.
Published: (2015-12-01)